About: Shifting emphasis from pharmacogenomics to theragnostics

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Shifting emphasis from pharmacogenomics to theragnostics Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Shifting emphasis from pharmacogenomics to theragnostics
Creator	Glatt, Stephen Lohr, James Ozdemir, Vural Reist, Christopher Tsuang, Ming Williams-Jones, Bryn
Source	Medline; PMC
abstract	What will be the role of theragnostic patents in upstream and downstream biomarker research?
has issue date	2006-01-01(xsd:dateTime)
bibo:doi	10.1038/nbt0806-942
bibo:pmid	16900136
has license	no-cc
sha1sum (hex)	c5422f41354c41e45115eb5c7dbd2e124b0b4920
schema:url	https://doi.org/10.1038/nbt0806-942
resource representing a document's title	Shifting emphasis from pharmacogenomics to theragnostics
has PubMed Central identifier	PMC7096916
has PubMed identifier	16900136
schema:publication	Nat Biotechnol
resource representing a document's body	covid:c5422f41354c41e45115eb5c7dbd2e124b0b4920#body_text
is schema:about of	named entity 'pharmacogenomics' named entity 'PHARMACOGENOMICS' named entity 'SHIFTING' named entity 'pharmacogenomics' named entity 'US Patent and Trademark Office' named entity 'patent rights' named entity 'clinical trials' named entity 'social factors' named entity 'pharmacogenomics' named entity 'antidepressant' named entity 'pharmaceutical' named entity 'proteomic' named entity 'drug therapies' named entity 'Basic research' named entity 'gene' named entity 'pharmacogenomic' named entity 'genomics' named entity 'biomarkers' named entity 'research-oriented' named entity 'drug development' named entity 'personalized medicine' named entity 'selective serotonin reuptake inhibitor' named entity 'biopharmaceutical company' named entity 'pharmacogenomics' named entity 'genetic testing' named entity 'non-genetic' named entity 'human diseases' named entity 'targeted therapies' named entity 'junk DNA' named entity 'drug therapy' named entity 'environmental factors' named entity 'drug targets' named entity 'phenotyping' named entity 'treatment options' named entity 'orphan drugs' named entity 'pharmacotherapy' named entity 'gene' named entity 'patent' named entity 'pharmacogenomics' named entity 'breast cancer' named entity 'biomarker' named entity 'biomarkers' named entity 'biomarker' named entity 'human diseases' named entity 'drug development' named entity 'patent' named entity 'proteomics' named entity 'market fragmentation' named entity 'genetic polymorphisms' named entity 'genetic biomarkers' named entity 'research laboratories' named entity 'coding regions' named entity 'gene' named entity 'biomarkers' named entity 'pharmaceutical industry' named entity 'Canada' named entity 'academic freedom' named entity 'drug prescriptions' named entity 'gene' named entity 'drug manufacturers' named entity 'bioethics' named entity 'gene' named entity 'metabolomics' named entity 'Huntington disease' named entity 'biomarker' named entity 'molecular genetic' named entity 'BCCA' named entity 'basic research' named entity 'gene' named entity 'metabolomics' named entity 'drug therapy' named entity 'pharmaceutical companies' named entity 'congenital' named entity 'drug discovery' named entity 'social science' named entity 'patent protection'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software